For example, programmed death-ligand 1 (PD-L1)/programmed cell death-1 (PD-1) levels, tumor mutational burden (TMB), and CD8 T cells can be used to assess the efficacy of immunotherapy. This evidence concerns the gene PDCD1 and neoplasm.